Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers

Journal of Clinical Pharmacology

Volumn 46, Issue 11, 2006, Pages 1290-1298

  Uchida, Shinya ^a   Yamada, Hiroshi ^a   Xiao, Dong Li ^b   Maruyama, Shuji ^a   Ohmori, Yuki ^a   Oki, Tomomi ^a   Watanabe, Hiroshi ^b   Umegaki, Keizo ^c   Ohashi, Kyoichi ^d   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^d OITA UNIVERSITY   (Japan)

Author keywords

CYP2C9; CYP3A4; Ginkgo biloba extract; Pharmacokinetic interaction

Indexed keywords

4 HYDROXYTOLBUTAMIDE; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; GINKGO BILOBA EXTRACT; MIDAZOLAM; MIDAZOLAM MALEATE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HERB DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; VOLUNTEER;

ADULT; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; GINKGO BILOBA; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDAZOLAM; PLANT EXTRACTS; TOLBUTAMIDE;

EID: 33749838677     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006292628     Document Type: Article

References (37)

1. Dergal JM, Gold JL, Laxer DA, et al. Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging. 2002;19:879-886.
2. Ness J, Johnson D, Nisly N. "Polyherbacy": herbal supplements as a form of polypharmacy in older adults. J Gerontol A Biol Sci Med Sci. 2003;58:M478.
3. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337-344.
4. Klepser TB, Doucette WR, Horton MR, et al. Assessment of patient's perceptions and beliefs regarding herbal therapies. Pharmacotherapy. 2000;20:83-87.
5. Brazier NC, Levine MAH. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther. 2003;10:163-169.
6. Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol. 2004;44:559-569.
7. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal dietary supplements: a source for drug interactions in transplant recipients, Transplantation. 2001;71:239-241.
8. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John's Wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2004;44:89-94.
9. Wang Z, Gorski JC, Hamman MA, Huang S, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70:317-326.
10. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet. 1997;33:103-121.
11. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999;16:478-485.
12. Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil. 2000;81:668-678.
13. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal, I. Progress Drug Res. 2001;56:1-76.
14. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997;278:1327-1332.
15. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002;71:1579-1589.
16. von Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol. 2004;56:1039-1044.
17. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59:425-432.
18. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemo. 2002;87:1075-1076.
19. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol. 2003;23:576-581.
20. Smith M, Lin MK, Zheng YP. An open trial of nifedipine-herb interactions: nifedipine with St John's wort, ginseng or ginkgo biloba [abstract]. Clin Pharmacol Ther. 2001;69:P86.
21. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72:276-287.
22. Greenblatt DJ, von Moltke LL, Luo Y, et al. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol. 2006;46:214-221.
23. Csillag K, Vereczkey L, Gachalyi B. Simple high-performance liquid chromatographic method for the determination of tolbutamide and its metabolites in human plasma and urine using photodiodearray detection. J Chromatogr. 1989;490:355-363.
24. Puglisi CV, Pao J, Ferrara FJ, de Silva JA. Determination of midazolam (Versed) and its metabolites in plasma by high-performance liquid chromatography. J Chromatography A. 1985;344:199-209.
25. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic beta-cell function in response to glucose loading in normal glucose tolerant individuals. J Clin Pharmacol. 2000;40:647-654.
26. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol. 2001;41:600-611.
27. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 2001;7:70-90.
28. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharm Exp Ther. 1990;252:442-447.
29. Srivastava PK, Yun CH, Beaune PH, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol. 1991;40:69-79.
30. Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Wu J, Umegaki K. Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sci. 2004;75:1113-1122.
31. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000;67:32-43.
32. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Eng J Med. 1997;336:1108.
33. Matthews MK. Association of Ginkgo biloba with intracerebral haemorrhage. Neurology. 1998;5:1933.
34. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 1989;36:89-96.
35. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72:718-728.
36. Ohnishi N, Kusuhara M, Yoshioka M, et al. Studies on interactions between functional foods or dietary supplements and medicines, I: effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull. 2003;26:1315-1320.
37. Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol. 2003;43:831-839.